Intravitreal Bevacizumab for Age-Related Macular Degeneration

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration

Clinical Trial Description

The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined. The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00347165
Study type	Interventional
Source	Asociación para Evitar la Ceguera en México
Contact
Status	Terminated
Phase	Phase 2
Start date	September 2005
Completion date	September 2006

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03963817` - Snapshot Camera for AMD
Recruiting	`NCT04929756` - Eye Movement Rehabilitation in Low Vision Patients
Completed	`NCT04779398` - Association of MPOD Values With Blue Light.
Terminated	`NCT03275753` - Visual Function Tests in Age-related Macular Degeneration
Recruiting	`NCT03609307` - Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial	Phase 2/Phase 3
Completed	`NCT02909985` - Visual Activity Evoked by Infrared in Humans After Dark Adaptation	N/A
Completed	`NCT02556723` - Intravitreal Injections of Ziv-aflibercept for Macular Diseases	N/A
Active, not recruiting	`NCT01943396` - Treatment of AMD With Rheohemapheresis /RHF/	Phase 4
Completed	`NCT00963339` - Age-Related Macular Degeneration (AMD) - Usability Study	N/A
Completed	`NCT00376701` - Combination Therapy for Age-Related Macular Degeneration.	Phase 2
Completed	`NCT00800995` - Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)	Phase 3
Completed	`NCT04689789` - OCTA and Retinal Angiomatous Proliferation
Completed	`NCT02567604` - Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
Completed	`NCT02173496` - Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
Recruiting	`NCT01991730` - Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients	N/A
Active, not recruiting	`NCT01657669` - Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results	Phase 4
Completed	`NCT00776763` - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab	Phase 2
Completed	`NCT00791570` - Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy	Phase 1
Completed	`NCT00413829` - Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)	Phase 2
Completed	`NCT00358345` - PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization	Phase 4